{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:59:59Z","timestamp":1790103599343,"version":"4.0.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Desmoid tumors are classified as borderline malignancies and are characterized by a high rate of local recurrence despite the absence of distant metastasis. Low-dose methotrexate combined with vinblastine, known as the methotrexate and vinblastine (MV) regimen, has been reported as an effective treatment for desmoid-type fibromatosis (DF). At our institution, we adopt a treatment strategy beginning with celecoxib as the first-line therapy, escalating to the MV regimen only in cases showing disease progression. This study evaluates treatment outcomes based on this protocol. At our institution, 10 patients diagnosed with DF between 2003 and 2025 received surgical resection and\/or pharmacotherapy. The standard approach involved initiating treatment with oral celecoxib; if no clinical improvement was observed, therapy was escalated to the MV regimen. Treatment response was assessed using Response Evaluation Criteria in Solid Tumors 1.1 criteria. Of the 10 cases, 1 achieved complete response, 5 showed partial response, 2 maintained stable disease, and 2 exhibited progressive disease, yielding a response rate of 60%. Among patients treated with the MV regimen, extended dosing intervals did not lead to tumor progression, and sustained suppression was observed in several cases. No grade 3 or 4 adverse events were reported. Celecoxib and the MV regimen appear to be effective and well-tolerated options for DF. Given its low toxicity and favorable tolerability, celecoxib should be considered the first-line treatment, especially since tumor control was achieved in half of the cases. Although tumor progression occurred in the remaining cases, disease control was subsequently achieved by introducing the MV regimen. These findings support recent trends favoring nonsurgical management and suggest that the celecoxib followed by the MV regimen strategy should be considered a primary therapeutic approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050665","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:01:40Z","timestamp":1789750900000},"page":"e50665","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of celecoxib and methotrexate\u2013vinblastine regimen in desmoid-type fibromatosis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1497-8689","authenticated-orcid":false,"given":"Masanori","family":"Kawano","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu, Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu, Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Itonaga","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu, Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kaku","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu, Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu, Oita Japan"},{"name":"Department of Advanced Medical Sciences, Faculty of Medicine, Oita University, Yufu, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260922","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.mayocp.2017.02.012","article-title":"Biology and treatment of aggressive fibromatosis or desmoid tumor.","volume":"92","author":"Skubitz","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"R2-20260922","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/jso.26566","article-title":"Surgical management of soft tissue tumors of the abdominal wall: a retrospective study in a high-volume sarcoma center.","volume":"124","author":"Neuberg","year":"2021","journal-title":"J Surg Oncol"},{"key":"R3-20260922","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1097\/PAS.0000000000000276","article-title":"Surgical resection margins in desmoid-type fibromatosis: a critical reassessment.","volume":"38","author":"Cates","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R4-20260922","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","article-title":"The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients.","volume":"127","year":"2020","journal-title":"Eur J Cancer"},{"key":"R5-20260922","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/15384047.2017.1373215","article-title":"Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing.","volume":"18","author":"Yang","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"R6-20260922","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s10637-017-0542-0","article-title":"Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis.","volume":"36","author":"Liu","year":"2018","journal-title":"Invest New Drugs"},{"key":"R7-20260922","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1158\/1078-0432.CCR-21-4504","article-title":"Systemic chemotherapies retain antitumor activity in desmoid tumors independent of specific mutations in CTNNB1 or APC: a multi-institutional retrospective study.","volume":"28","author":"Nathenson","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R8-20260922","doi-asserted-by":"crossref","first-page":"e0276047","DOI":"10.1371\/journal.pone.0276047","article-title":"Preclinical efficacy of the Wnt\/beta-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors.","volume":"17","author":"Braggio","year":"2022","journal-title":"PLoS One"},{"key":"R9-20260922","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/carcin\/bgy038","article-title":"Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras\/MEK\/ERK and PI3K\/Akt\/mTOR pathways.","volume":"39","author":"Rosenberg","year":"2018","journal-title":"Carcinogenesis"},{"key":"R10-20260922","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5152\/j.aott.2021.21033","article-title":"Extra-abdominal desmoid fibromatosis: an evaluation of clinical factors affecting local recurrence rates.","volume":"55","author":"Coskun","year":"2021","journal-title":"Acta Orthop Traumatol Turc"},{"key":"R11-20260922","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12957-016-0944-z","article-title":"Complete remission of pancreatic head desmoid tumor treated by COX-2 inhibitor-a case report.","volume":"14","author":"Wang","year":"2016","journal-title":"World J Surg Oncol"},{"key":"R12-20260922","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1245\/s10434-008-0285-4","article-title":"Desmoids: a revelation in biology and treatment.","volume":"16","author":"Francis","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R13-20260922","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1111\/cas.14626","article-title":"Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: a phase II clinical trial.","volume":"111","author":"Nishida","year":"2020","journal-title":"Cancer Sci"},{"key":"R14-20260922","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S1470-2045(19)30276-1","article-title":"Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.","volume":"20","author":"Toulmonde","year":"2019","journal-title":"Lancet Oncol"},{"key":"R15-20260922","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/07357907.2019.1656731","article-title":"Radiotherapy in the treatment of primary or recurrent unresectable desmoid tumors of the neck.","volume":"37","author":"Niu","year":"2019","journal-title":"Cancer Invest"},{"key":"R16-20260922","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/jjco\/hyab146","article-title":"Trends in diagnostic and therapeutic strategies for extra-abdominal desmoid-type fibromatosis: Japanese musculoskeletal oncology group questionnaire survey.","volume":"51","author":"Murase","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"R17-20260922","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R19-20260922","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.1999.17.1.158","article-title":"Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy.","volume":"17","author":"Ballo","year":"1999","journal-title":"J Clin Oncol"},{"key":"R20-20260922","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/00000658-199906000-00014","article-title":"The enigma of desmoid tumors.","volume":"229","author":"Lewis","year":"1999","journal-title":"Ann Surg"},{"key":"R21-20260922","first-page":"464","article-title":"Immunological aspects of neoplasia.","volume":"40","author":"Bukovsky","year":"1975","journal-title":"Cesk Gynekol"},{"key":"R22-20260922","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/PPO.0000000000000254","article-title":"Long-term efficacy of methotrexate plus vinblastine\/vinorelbine in a large series of patients affected by desmoid-type fibromatosis.","volume":"23","author":"Palassini","year":"2017","journal-title":"Cancer J"},{"key":"R23-20260922","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors.","volume":"388","author":"Gounder","year":"2023","journal-title":"N Engl J Med"},{"key":"R24-20260922","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/jamaoncol.2024.1805","article-title":"Current management of desmoid tumors: a review.","volume":"10","author":"Kasper","year":"2024","journal-title":"JAMA Oncol"},{"key":"R25-20260922","doi-asserted-by":"crossref","first-page":"e35603","DOI":"10.1002\/cncr.35603","article-title":"Desmoid tumors: old and new drugs for a rare and challenging disease.","volume":"131","author":"Kasper","year":"2025","journal-title":"Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:02:47Z","timestamp":1790100167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050665"}},"subtitle":["A retrospective cohort study"],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":24,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050665","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"2025-12-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}